ClinicalTrials.gg
RecruitingNCT06368505Updated Apr 16, 2024

Platelet-Rich Plasma Injection Versus Hydrodissection in the Treatment of Carpal Tunnel Syndrome

An interventional study of ultrasound guided PRP injection and ultrasound guided hydrodissection in Carpal Tunnel Syndrome, sponsored by Osama Ahmed Elshafei. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Osama Ahmed Elshafei · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Carpal Tunnel Syndrome with a site in Egypt — 20 open to participants now, 22 under way, 1 of them phase 3. Carpal Tunnel Syndrome · Egypt.

Planned enrollment
19th of 53
64 · median 60
Started
2024
with 4 others
No phase
44 of 64
12 open now
Primary completion
2024-06
later than 7 of 21 live
Registered
43rd of 64
by date

Among the 64 studies in Carpal Tunnel Syndrome with a site in Egypt, this one is the 19th largest by planned enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2024, is one of 44 with no phase, reaches primary completion later than 7 of the 21 other live ones, and was the 43rd registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

20 of the 64 studies in Carpal Tunnel Syndrome with a site in Egypt are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Carpal Tunnel Syndrome with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the efficacy of Ultrasound-Guided Platelet-Rich Plasma Injection versus Hydrodissection (using 2ml saline, 2ml dexamethasone and 1ml lidocaine) in the Treatment of Carpal Tunnel Syndrome. The main questions it aims to answer are:

  • Which modality is more effective in reducing symptoms and improving function in patients with Carpal tunnel syndrome
  • Asses safety profile of both methods

Participants will:

  • Randomized to one of the two arms
  • Visit the clinic 1 and 3 months after intervention
  • Assessed for efficacy and safety of the intervention
Read the detailed description

The medical records of patients diagnosed with carpal tunnel syndrome will be reviewed using a computerized carpal tunnel syndrome sheet including all variables for each patient assessing the symptoms and the functional condition by assessing changes in the usual daily routines. The assessment of the patients was done before and after the intervention (1 and 3 months later).

The CSA is obtained (in mm² at distal wrist crease) using ultrasound. Then the CTS grading was determined via US staging 9-13, 13-15, >15 as mild, moderate and severe respectively.

Ultrasound-Guided Intracarpal Injection. High-resolution US examination will be done by using a GE Logiq E9 with ML6-15-D Matrix linear array probe (USA). Under sterile conditions, a 25-gauge needle will be used using ulnar approach and under real time visualization the needle will be guided to the superficial ulnar aspect of the median nerve. The patients will be randomized into two groups

PRP group:

whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach

Hydrodissection group:

5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL.

All patients will be observed for 30-min post-injection for possible side effects before discharge.

Outcome Measurements: All outcome assessments will be measured at 1 and 3 months after intervention.

Primary Outcome Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) and The visual analog scale (VAS) to assess the efficacy of interventions Secondary Outcome The cross-sectional area (CSA) of the Median nerve will be measured by the same US machine, Measurements were repeated 3 times and averaged for further

03

Conditions studied

  • Carpal Tunnel Syndrome

Keywords

  • carpal tunnel
  • ultrasound guided intervention
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed clinically as carpal tunnel syndrome with at least 3 months of symptoms and confirmed electro-physiologically as carpal tunnel syndrome

Exclusion criteria

Exclusion Criteria:

  • Onset of carpal tunnel syndrome during pregnancy
  • Co-existence of brachial plexopathy or thoracic outlet syndrome by clinical examination
  • Previous carpal tunnel decompressive surgery or injection in carpal tunnel
  • Patients with infection or local edema at the site of injection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Platelet rich plasma

    3 ml PRP injection

    Other: ultrasound guided PRP injection

  • Experimental
    hydrodissection

    5ml injectate

    Other: ultrasound guided hydrodissection

Interventions

  • Otherultrasound guided PRP injection

    whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach

  • Otherultrasound guided hydrodissection

    5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL

06

What researchers measure

Primary outcomes

  1. Boston Carpal Tunnel Syndrome Questionnaire (BCTQ)

    Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) is a patient-based questionnaire, consists of two main scales: Symptom Severity Scale (SSS): Measures the severity of symptoms related to CTS. Functional Status Scale (FSS): Assesses functional limitations caused by CTS. Each scale contains several items, and patients rate their symptoms or functional difficulties on a scale from 1 to 5. A score of 1 indicates no symptoms or functional difficulty. A score of 5 represents maximum symptoms or inability to perform the task1. Interpretation: Higher scores on both scales indicate worse symptoms or greater functional impairment due to CTS.

    Time frame: before the intervention,1 and 3 months after intervention

  2. The visual analog scale (VAS)

    The Visual Analogue Scale (VAS) is a simple assessment tool used to measure pain intensity. The VAS consists of a straight horizontal line, usually 10 centimetres (cm) in length. One end of the line represents "no pain," while the other end represents "the worst pain ever experienced." Patients are asked to rate their current level of pain by placing a mark on the line. Using a ruler, the score is determined by measuring the distance (in millimetres) from the "no pain" anchor to the patient's mark. The resulting score ranges from 0 to 100, with a higher score indicating greater pain intensity.

    Time frame: before the intervention,1 and 3 months after intervention

Secondary outcomes

  1. The cross-sectional area (CSA) of the Median nerve

    Using the ultrasound, the CSA is obtained (in mm² at distal wrist crease) by utilizing the tracing function on the US machine by direct tracing around the inner margin of the epineurium but with no weaving in between each fascicle. Measurements were repeated three times and average value was used for statistical evaluation.

    Time frame: before the intervention and 3 months after intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2024, 5 months after the start.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 5 months is below that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2024
First posted
Apr 16, 2024
StartActual
Jan 16, 2024
Primary completionEst.
Jun 16, 2024
CompletionEst.
Jul 16, 2024
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06368505
Lead sponsor
Osama Ahmed Elshafei
Responsible party
Osama Ahmed Elshafei (lecturer of neurology, Mansoura University) — Sponsor-investigator
First posted
Apr 16, 2024
Start date
Jan 16, 2024
Primary completion
Jun 16, 2024 (estimated)
Completion
Jul 16, 2024 (estimated)
Last update
Apr 16, 2024

Study contacts

osama elshafei, MD, PHD
Contact
osama_elshafei@mans.edu.eg
+201211182182

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion